No abstract available.
Inflammatory Breast Neoplasms* ; Neoplasm Metastasis* ; Stomach Neoplasms*

PURPOSE: The objective of this study was to test the efficacy and toxicity of adriamycin plus docetaxel as the primary chemotherapy for women with advanced breast carcinoma, and including those patients with inflammatory breast cancer. Our study also evaluated the clinicopathologic factors influencing the response rate to neoadjuvant chemotherapy. METHODS: Twenty-eight patients who underwent neoadjuvant chemotherapy between 2002 and 2004 were included for this study. The patients were treated with adriamycin (50 mg/m2; intravenous bolus) followed by docetaxel (75 mg/m2; 1-hr intravenous infusion) on the first day of each cycle for an average four cycles. We analysed the response rate to adjuvant chemotherapy by reviewing the post operative pathologic report. Additionally we compared the clincopathologic factors related to the response rate. Statistical analyses were performed with 2-tests and using SPSS 11.0. RESULTS: The mean age at diagnosis was 48.9 yr old (range 29-63 yr). The tumoral response to neoadjuvant chemotherapy was, 3 patients (10.7%) showed a complete response (CR), 21 patients (75%) showed a partial response (PR). and which about lymph node were that 15 patients (75%) have shown responder, 5 patients (25%) have shown non-responder. The overall response rate to neoadjuvant chemotherapy was 85.7%. The preoperative serum-CEA level was influenced the response rate to neoadjuvant chemotherapy (p=0.025). Grade 3 or 4 neutropenia was recorded in 81.9% of the patients (N=59/72). Grade 3 or 4 anemia was recorded in 2.8% of the patients. CONCLUSION: Neoadjuvant chemotherapy with adriamycin plus docetaxel was effective treatment for patients with locally advanced breast cancer. The preoperative serum CEA level colud be the important factor for the neoadjuvant chemotherapy response rate.
Anemia ; Breast ; Breast Neoplasms ; Chemotherapy, Adjuvant ; Doxorubicin ; Female ; Humans ; Inflammatory Breast Neoplasms ; Lymph Nodes ; Neutropenia ; Taxoids

Female ; Humans ; Breast Neoplasms/surgery* ; Inflammatory Breast Neoplasms ; Mastectomy ; Medical Oncology

Tuberculosis of the breast is an extremely rare disease. That needs to be differentiated from inflammatory breast cancer, acute or subacute breast abscess and actinomycosis of the breast in order for it to be treated effectively. However, tuberculosis of the breast is difficult to diagnose because of the diagnostic methods used. In addition, significant time is needed to identify tuberculosis by culture. We experienced a case of tuberculosis of the breast that developed during the anti-tuberculous medication. The patient was diagnosed quickly using tuberculosis PCR and treated with a combination of a surgical excision and anti-tuberculous medication.
Abscess ; Actinomycosis ; Breast* ; Humans ; Inflammatory Breast Neoplasms ; Polymerase Chain Reaction ; Rare Diseases ; Tuberculosis*

Metastasis of signet ring cell gastric carcinoma to the breast is extremely rare. The common clinical findings are redness, edematous skin and pain, and these findings are similar to those of inflammatory breast cancer. We describe here a case of metastatic signet ring cell gastric carcinoma to the bilateral breasts, and this presented as bilateral palpable breast lumps after the patient had undergone radical total gastrectomy two years previously.
Breast ; Carcinoma, Signet Ring Cell ; Gastrectomy ; Humans ; Inflammatory Breast Neoplasms ; Neoplasm Metastasis ; Skin ; Stomach

The breast cancer is the second most common malignancy in pregnancy after cervical cancer. Pregnancy- associated breast caner tends to show unfavorable prognosis, because it is diagnosed at more advanced stage due to delay of diagnosis and treatment. For appropriate management, collaboration with physicians and obstetricians should make precise decisions considering gestational weeks and cancer stage at the time of diagnosis in a point of view from mother and fetus. A case of successful gestation and delivery after chemotherapy in a woman with inflammatory breast cancer diagnosed in the second trimester is presented with review of literature.
Breast Neoplasms* ; Breast* ; Cooperative Behavior ; Diagnosis ; Drug Therapy ; Female ; Fetus ; Humans ; Inflammatory Breast Neoplasms ; Mothers ; Pregnancy ; Pregnancy Trimester, Second ; Prognosis ; Uterine Cervical Neoplasms

PURPOSE: To describe, evaluate and compare radiologic and clinical findings in the diagnosis of inflammatory breast carcinoma. MATERIALS AND METHODS: We retrospectively analysed the clinical and radiologic findings of mammography, ultrasonography and computed tomography in 11 women aged 31-75 (mean 46) years with inflammatory breast carcinoma. In three women, follow-up radiologic studies were also assessed. RESULTS: The left breast (7 cases) was more commonly involved than the right (4 cases). A Palpable mass (9 cases) and palpable axillary lymphadenopathy (8 cases) were the most common clinical findings. In nine of ten women, mammography revealed trabecular thickening, skin thickening, and nipple retraction. Mass, axillary lymphadenopathy and diffuse increased density of the breast parenchyma were also frequently found. Sonography showed that skin thickening and axillary lymphadenopathy were present in three women; obliteration of the interface between subcutaneous fat and parenchyma, as well as lymphatic engorgement, were also observed. In one woman, mass, skin thickening, nipple retraction and axillary lymphadenopathy were seen on CT. For the assessment of skin thickening, radiologic findings were better than clinical findings. During follow-up, radiologic and clinical findings showed close correlation. CONCLUSION: In the diagnosis and assessment of inflammatory breast carcinoma, radiologic findings provide valuable information.
Breast ; Diagnosis ; Female ; Follow-Up Studies ; Humans ; Inflammatory Breast Neoplasms* ; Lymphatic Diseases ; Mammography ; Nipples ; Retrospective Studies ; Skin ; Subcutaneous Fat ; Ultrasonography

Tuberculous mastitis is a rare manifestation of mycobacterium tuberculosis infection. It mimics inflammatory breast cancer or other pyogenic inflammations. In most of the tuberculous mastitis reports, coexisting or prior tuberculosis infection and secondary infection of the breast by direct spread via axillary or cervical lymphadenopathy, or hematogenous spread have been noted. We describe the mammographic and ultrasonographic findings of a case of diffuse type mycobacterium tuberculosis of the breast showing diffuse edema which was confirmed as tuberculosis through biopsy and had no evidence of old or concurrent pulmonary tuberculosis on chest computed tomography.
Biopsy ; Breast ; Coinfection ; Edema ; Female ; Inflammation ; Inflammatory Breast Neoplasms ; Lymphatic Diseases ; Mammography ; Mastitis ; Mycobacterium ; Mycobacterium tuberculosis ; Thorax ; Tuberculosis ; Tuberculosis, Pulmonary

Primary neuroendocrine carcinoma of the breast (NECB) is a very rare type of invasive breast carcinoma. Most NECBs appear on breast imaging as solid masses of varied shapes and margins, and have worse clinical outcomes than does invasive ductal carcinoma, not otherwise specified. However, there have been no reports to date regarding NECB with features of inflammatory breast carcinoma. Here, we describe the clinical, radiol-ogic, and pathologic findings of the first reported case of primary NECB presenting as inflammatory breast carcinoma. The patient complained of diffuse right breast enlargement and erythema. Mammography identified severe breast edema and axillary lymphadenopathy. Ultrasound detected an irregular, angular, hypoechoic mass with dermal lymphatic dilatation. On magnetic resonance imaging, the mass had rim enhancement and the entire right breast showed heterogeneous enhancement with malignant kinetic features. Pathology identified the mass as a primary NECB with positive for synaptophysin, CD56, estrogen and progesterone receptors.
Breast Neoplasms ; Breast* ; Carcinoma, Ductal ; Carcinoma, Neuroendocrine* ; Dilatation ; Edema ; Erythema ; Estrogens ; Humans ; Inflammatory Breast Neoplasms* ; Lymphatic Diseases ; Magnetic Resonance Imaging ; Mammography ; Pathology ; Receptors, Progesterone ; Synaptophysin ; Ultrasonography

PURPOSE: Given the promising activity of capecitabine and vinorelbine in metastatic breast cancer, this randomized phase II trial evaluated the efficacy and safety of this combination as neoadjuvant chemotherapy in breast cancer. MATERIALS AND METHODS: Patients with operable breast cancer (n=75) were randomly assigned to receive either four cycles of adriamycin 60 mg/m2 plus cyclophosphamide 600 mg/m2 every 3 weeks followed by four cycles of docetaxel 75 mg/m2 every 3 weeks (AC-D) or four cycles of capecitabine 2,000 mg/m2 (day 1-14) plus vinorelbine 25 mg/m2 (days 1 and 8) every 3 weeks followed by four cycles of docetaxel 75 mg/m2 (CV-D). The primary endpoint was pathologic complete response (pCR) in the primary breast (ypT0/is). RESULTS: Most patients (84%) had locally advanced (n=41) or inflammatory breast cancer (n=22). pCR rates in the primary breast were 15% (95% confidence interval [CI], 7% to 30%) and 11% (95% CI, 4% to 26%) in the AC-D and CV-D groups, respectively. The overall response rates and 5-year progression-free survival rates in the AC-D and CV-D groups were 62% and 64%, and 51.3% (95% CI, 34.6% to 68.0%) and 30.2% (95% CI, 13.3% to 47.1%), respectively. Although both regimens were well tolerated, CV-D showed less frequent grade 3-4 neutropenia and vomiting than AC-D, whereas manageable diarrhea and hand-foot syndrome were more common in the CV-D group. CONCLUSION: CV-D is a feasible and active non-anthracycline-based neoadjuvant chemotherapy regimen for breast cancer.
Anthracyclines ; Breast ; Breast Neoplasms* ; Cyclophosphamide* ; Diarrhea ; Disease-Free Survival ; Doxorubicin* ; Drug Therapy* ; Hand-Foot Syndrome ; Humans ; Inflammatory Breast Neoplasms ; Neoadjuvant Therapy ; Neutropenia ; Polymerase Chain Reaction ; Vomiting